Breaking News

Amgen Breaks Ground for New NC Biomanufacturing Facility

The facility will use new technologies that maximize efficiency and help ensure the ability to produce a broad range of medicines.

By: Kristin Brooks

Managing Editor, Contract Pharma

Amgen broke ground at its newest biomanufacturing facility in Holly Springs, NC. The facility, expected to be operational by 2025, will support Amgen’s medicines that treat illnesses such as cancer and heart disease.
 
“Amgen is adding to North Carolina’s strong economic growth with the addition of its newest manufacturing plant to our already robust biomanufacturing ecosystem,” said Roy Cooper, Governor of North Carolina. “We welcome Amgen’s choice to build a state-of-the-art facility in our world-renowned Research Triangle region, bringing more than 350 high-quality new jobs to our state.”
 
The facility will use new technologies that maximize efficiency and help ensure the ability to produce a broad range of medicines. It will be built to environmental standards with goal of reducing water usage and waste and achieving carbon neutrality by 2027. Construction management and design services for this new state-of-the-art facility are being led by Integrated Project Services, LLC.
 
“For over four decades, Amgen has been an innovative leader in the manufacturing of complex biologics. Our commitment to continuous improvement and our significant investments in new technologies have enabled us to further accomplish our mission to serve patients while science rapidly evolves,” said Robert A. Bradway, chairman and chief executive officer of Amgen. “We are delighted to be building our newest facility in North Carolina, a major hub for biopharmaceutical innovation.”
 
Amgen’s selection of North Carolina was driven, in part, by access to diverse talent. Amgen is a founding member of the OneTen Coalition, a coalition of 35 of the world’s largest, best-known companies which plans to hire one million Black Americans into good-paying, family-sustaining jobs over the next ten years. To achieve this goal, Amgen will work with businesses, educational institutions, and training partners to better develop, retain and advance diverse talent, focusing on Black Americans without four-year college degrees.
 
Amgen has approximately 24,000 employees worldwide. The company has manufacturing facilities in California, Ireland, Netherlands, Ohio, Puerto Rico, Rhode Island and Singapore.
 

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters